You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍捱沽 泰格(03347.HK)、三葉草(02197.HK)及來凱(02105.HK)挫約9.5%-10%
恆指今早回升至16,941無以為繼,掉頭低見16,710,創52周新低,現報16,723,跌107點或0.6%,總成交額804億元。 醫藥股中,除藥明系跌近5%-24%外,其餘普遍跑輸大市,三葉草生物-B(02197.HK)及來凱醫藥-B(02105.HK)跌一成,分別報0.63元及17.34元,後者股價失守50天線(18.6元)。泰格醫藥(03347.HK)見超過52周新低,最低見36.4元,現報36.8元,跌9.4%。醫藥相關股凱萊英(06821.HK)跌12%報90.85元,股價失守100天及250天線。 藍籌中生(01177.HK)、康諾亞-B(02162.HK)、再鼎醫藥(09688.HK)及君實生物(01877.HK)挫逾5%-5.5%,分別報3.54元,52.9元、20.25元及22.35元。 艾美疫苗(06660.HK)、復星醫藥(02196.HK)、百濟神州(06160.HK)、四環醫藥(00460.HK)、康寧傑瑞製藥-B(09966.HK)、康希諾(06185.HK)、聯邦制藥(03933.HK)、諾誠健華(09969.HK)、信達生物(01801.HK)、騰盛博藥-B(02137.HK)及藍籌石藥(01093.HK)跌逾2%-4.5%,其中石藥失守10天及20天線。 開拓藥業(09939.HK)低位1.74元,再創上市新低後獲承接,高見2.05元,現報1.88元,止跌回升2.7%。神威藥業(02877.HK)升1.9%報6.93元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account